Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — H2 2019 Earnings Presentation
19 slides from Moberg Pharma Ab's earnings presentation, Feb 11, 2020
Slide 1: Interim report July – December 2019
Interim report July – December 2019 For the extended fiscal year July 2019 ‐ December 2020 February 11th, 2020 at 3:00 p.m. CET. Dial‐in: SE: +46 8 505 583 69, US: +1 833 526 83 82. Anna Ljung, CEO
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Moberg Pharma 2.0
Moberg Pharma 2.0 Pipeline progress Financial performance Focus forward
Slide 4: Moberg Pharma 2.0
Moberg Pharma 2.0 COMMERCIAL BUSINESS PIPELINE ASSETS Divestment for $155m 2 PRODUCTS IN PHASE 3 completed March 29 MOB‐015 BUPI Redemption of shares Topical terbinafine Bupivacaine lozenge against nail fungus against OM payed Nov 26, 46.50 SEK per share Distributor sales Potential market leaders wi
Slide 5: Pipeline progress
Moberg Pharma 2.0 Pipeline progress Financial performance Focus forward
Slide 6: Significant events in July – December 2019
Significant events in July – December 2019 Primary endpoint reached in the North American phase 3 study MOB‐015 has the potential to become the future market leader in onychomycosis. Seventy percent of the patients were fungus free, which is world leading for a topical treatment, but increased hydra
Slide 7: Primary endpoint reached in the North American phase 3 study
Primary endpoint reached in the North American phase 3 study • The North American Phase III study for MOB‐015 was conducted at 32 sites in USA and Canada. 365 patients were randomized 2:1 to MOB‐015 and its vehicle. Patients were treated once daily for 48 weeks, with last follow‐up at week 52 • Key
Slide 8: MOB-015 delivered high mycological cure with an early onset, but lower complete cure than expected
MOB‐015 delivered high mycological cure with an early onset, but lower complete cure than expected Complete Current treatments Mycological cure rate cure rate 12W 24W 52W 52W MOB‐015 (topical Terbinafine) 37% 55% 70% 4.5% X Ciclopirox (Penlac) 30% 5.5‐8.5% Efinaconazole (Jublia) 51‐53% 15‐18% Tavabo
Slide 9: Relationship mycological cure - complete cure rate
Relationship mycological cure ‐ complete cure rate for topical and oral onychomycosis products 80% MOB‐015 Oral terbinafine 70% 60% mycological cure rate 50% 40% 30% 20% 10% 0% 0% 5% 10% 15% 20% 25% 30% 35% 40% complete cure rate Source: U.S. prescribing information for each drug 9
Slide 10: The vehicle delivers the drug but also confounds the clinical cure assessment
The vehicle delivers the drug but also confounds the clinical cure assessment After analyzing the photos and the data, the company experts and KOLs found that: • The vehicle enables high delivery of terbinafine through the nail plate, • The vehicle's hydrating properties also cause transient whiteni
Slide 11: Shorter treatment - a solution to the problem
Shorter treatment ‐ a solution to the problem Based on the expert discussions, and analysis of all available data including the phase 3 data, earlier trials, and literature data, the company experts and KOLs identified a solution: • A shorter dosing regimen followed by a maintenance period is likely
Slide 12: Strong support from Key Opinion Leaders
Strong support from Key Opinion Leaders Dr Boni Elewski, Professor and Chair of the Department of Dermatology, University of Alabama. “The high mycological cure rate demonstrated is very impressive and given the rapid onset of the antifungal effect, MOB‐015 offers exciting benefits. I will definitel
Slide 13: Financial performance
Moberg Pharma 2.0 Pipeline progress Financial performance Focus forward
Slide 14: P&L – MUSD 5 received in upfront for MOB-015 in Japan
P&L – MUSD 5 received in upfront for MOB‐015 in Japan Oct‐Dec Apr‐Jun Jul‐Dec Jan‐Jun (SEK thousand) 2019 2019 2019 2019 Continuing operations Net revenue 2,669 ‐ 50,488 15,554 Gross profit 2,669 0 50,488 15,554 Selling expenses ‐131 ‐222 ‐293 ‐788 Business development and administrative expenses ‐6
Slide 15: Balance Sheet – SEK 69 million in current assets, debt free
Balance Sheet – SEK 69 million in current assets, debt free (SEK thousand) 2019.12.31 2019.06.30 Assets Intangible assets 284,290 255,654 Property, plant and equipment 46 80 Right‐of‐use assets 9,259 10,493 Deferred tax asset 4,074 11,617 Total non‐current assets 297,669 277,844 Trade receivables an
Slide 16: Cash Flow - 837 MSEK was distributed to shareholders in Nov
Cash Flow ‐ 837 MSEK was distributed to shareholders in Nov Oct‐Dec Apr‐Jun Jul‐Dec Jan‐Jun (SEK thousand) 2019 2019 2019 2019 Operating activities Operating profit before financial items from continuing operations ‐4,795 ‐9,172 36,962 ‐4,220 Operating profit before financial items from discontinued
Slide 17: Focus forward
Moberg Pharma 2.0 Pipeline progress Financial performance Focus forward
Slide 18: Focus on delivering pipeline value
Focus on delivering pipeline value Aiming to create the next market leader in onychomycosis Continuing to create value for the shareholders of Moberg Pharma with a business strategy centered around MOB‐015 • MOB‐015 Topline‐results: – Delivered December 2019 for North America, primary endpoint met –
Slide 19: Moberg Pharma AB (Publ)
Moberg Pharma AB (Publ) Gustavslundsvägen 42, 5 tr. 167 51 Bromma mobergpharma.se